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In this issue of Cell Stem Cell, Iglesias-Bartolome et al. (2012) show that mTOR inhibition with rapamycin
protects against mucositis in mice, suggesting potential treatment strategies against this harmful side effect
of anticancer therapies. In normal tissues, rapamycin prevents epithelial stem cell senescence by reducing
oxidative stress through increased MnSOD.Surveys of patients undergoing aggres-
sive treatment for cancer or those who
have undergone bonemarrow transplants
often cite the development of painful
mouth ulcers, termed mucositis, as their
most dreaded and debilitating side effect
(Sonis, 2011). These exquisitely tender
lesions that develop on the mucosa
of the mouth and oropharynx appear
in most patients receiving combined
chemotherapy and radiation and often
leave the patient unable to eat or drink.
Up to now, the management of this con-
dition has been mostly supportive, with
patients offered opioid-strength pain relief
and hydration. That supportive but mostly
ineffective strategy might however
change if the findings from a paper in
this issue of Cell Stem Cell can be
extended from mice to humans (Iglesias-
Bartolome et al., 2012). This new data
suggests that pharmacological inhibition
of the mechanistic target of rapamycin
(mTOR) might eventually provide the
basis for a molecular salve to protect
patients from this prevalent and painful
condition.
In this new study by Iglesias-Bartolome
and colleagues, the authors began by
asking whether the addition of the mTOR
inhibitor rapamycin might sensitize
head and neck cancer cells to radiation
therapy. This made sense given that
radiation is a major therapeutic approach
for these tumors and mTOR is often acti-
vated in these malignancies. Like most
good ideas, this notion of course turned
out to be wrong. Yet as luck would have
it, the authors realized that while mTOR
inhibition did not appreciably alter their
tumor cell lines, rapamycin treatment
had a remarkable and completely unex-
pected effect on their control normal oralkeratinocytes (NOKs). These NOK cells
can be isolated from biopsies obtained
from the mouth of healthy human volun-
teers and the explanted cells can be
demonstrated to possess long term self-
renewal capacity, thus indicating the
presence of epithelial stem cells with
tissue regenerative capacity. The authors
observed that rapamycin treatment had
little effect on the proliferation of NOKs
but dramatically extended the replicative
lifespan of these cells. Indeed, the authors
calculate that in their culture system,
a single epithelial stem cell that would
normally give rise to 106 cells before
undergoing senescence would, after
rapamycin treatment, be able to give rise
to nearly 1017 progeny before exhaustion.
In addition, the secretion of various
inflammatory cytokines that are normally
robustly produced by senescent cells
was dramatically reduced after rapamycin
exposure. This might be particularly
important as there is growing evidence
that such proinflammatory cytokines
might fuel mucositis (Sonis, 2011). The
authors next showed that the premature
senescence induced by exogenous
gamma irradiation was also inhibited
in rapamycin-treated NOKs apparently
because mTOR inhibition reduced the
levels of reactive oxygen species (ROS).
The basis for this reduced oxidative stress
was traced to a heretofore unknown role
for mTOR in regulating the expression
of the mitochondrial antioxidant pro-
tein manganese superoxide dismutase
(MnSOD). In rapamycin treated cells,
lower levels of ROS produced lower levels
of DNA damage, and therefore resulted in
diminished expression of senescence-
associated cell cycle inhibitors such as
p16INK4A. These tantalizing observationsCell Stem Cell 11, Swere then extended to an in vivo model
where mice received high dose fraction-
ated radiation (6 Gy to the head and neck
for 5 consecutive days). This regimen led
to activation of mTOR in the irradiated
tissues that could be suppressed by
rapamycin treatment. Remarkably, intra-
peritoneal injection with rapamycin ap-
peared to almost completely suppress
the development of radiation-induced
oral ulcerations. This finding suggests
that as observed in vitro, mTOR inhibitors
might lessen radiation-induced senes-
cence and thus preserve the proliferative
and intrinsic reparative properties of
resident epithelial stem cells (Figure 1).
These observations add to a growing
connection between mTOR activity and
stem cell function. Previous work has
suggested that constitutive activation of
mTOR in hematopoietic stem cells
(HSCs) led to an initial increase in the
proliferation of HSCs, followed by
a long-term decline in self-renewal (Chen
et al., 2008). Again, this decline in self-
renewal appeared to result from an
increase in ROS levels within the mTOR
hyperactivated stem cells. However, in
this case, the rise in ROS levels was
traced back to an increase in mitochon-
drial number and potentially ROS pro-
duction (Chen et al., 2008) rather than,
as seen in the current manuscript,
a change in antioxidant defenses. Indeed,
there appears to be an important and
growing connection between mTOR
activity, mitochondrial number and func-
tion, and overall redox homeostasis. For
instance, inhibiting mTOR genetically or
pharmacologically can dramatically and
sometimes rapidly alter mitochondrial
metabolism in both cells and tissues
(Laplante and Sabatini, 2012).eptember 7, 2012 ª2012 Elsevier Inc. 287
Figure 1. The Role of mTOR in Radiation-Induced
Mucositis
Irradiation of epithelial stem cells leads to mTOR activation.
Inhibiting this activation with rapamycin treatment reduces
the levels of ROS, inflammatory cytokine production, and over-
all DNA damage, and thereby prevents radiation-induced
senescence. Rapamycin may also protect against the prema-
ture differentiation or apoptosis of stem and progenitor cells.
These protective effects combine to prevent the appearance
of clinically debilitating side-effects such as mucositis.
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In TranslationWhile the current study in Cell
Stem Cell deals primarily with
premature epithelial stem cell
senescence induced by radiation,
there is some evidence that the
mechanisms described might be
broadly applicable. Indeed, the
authors of this study had previously
shown that persistent Wnt signaling
in the skin led to an initial hyperpro-
liferative phase followed by epithe-
lial stem cell exhaustion (Castilho
et al., 2009). Surprisingly, these
Wnt-induced stem cell effects were
also mediated by increased mTOR
signaling. In this model, as was
seen with irradiation, Wnt-induced
epidermal stem cell exhaustion
was associated with increased
DNA damage that was reduced by
mTOR inhibition. This increase in
DNA damage has also been seen
in other models of constitutive
Wnt signaling associated with
accelerated aging models (Liu
et al., 2007). Given the role of Wnt
signaling in normal epithelial stem
cell renewal, and the observation
that an increase in DNA damage
is a signature of aged stem cells
(Rossi et al., 2007), these results
suggest that the mTOR inhibition
may be a general strategy to pre-serve and prolong the stem and progen-
itor population.
While the broader implication for stem
cell biology needs further study, the new
results by Iglesias-Bartolome may have
more immediate and practical implica-
tions for cancer patients suffering from
radiation-induced mucositis. Rapamycin
is already FDA approved for the treat-
ment of graft rejection and coronary
restenosis after angioplasty. Moreover,
the compound is currently being tested
for its efficacy in a wide range of
diseases ranging from common malig-
nancies to rare conditions such as the
lung disease lymphangioleiomyomatosis.
While systemic use of rapamycin is not288 Cell Stem Cell 11, September 7, 2012 ª2without significant toxicities, the accessi-
bility of the oral mucosa suggests other
approaches are possible. For example,
it might be possible to use a mouthwash
or gel spiked with rapamycin, or even
potentially newer, more potent mTOR
inhibitors, to provide targeted relief
from radiation-induced mucositis. This
strategy would be conceptually similar
to the currently approved and widely
marketed use of topical cyclosporine
(Restasis) for the treatment of dry
eyes. Both cyclosporine and rapamycin
are potent immunosuppressives when
given orally; however, when given as
eye drops or mouthwash, it is possible
to achieve high local concentrations012 Elsevier Inc.while avoiding the corresponding
systemic toxicities. It should be
noted that based on the current
study, the beneficial effects of
a theoretical rapamycin mouth-
wash (we will hereby christen it
RapaWash) are not a result of its
immunomodulatory effects, but are
rather due to the role of mTOR
in regulating the levels of ROS
within the epithelial stem cell com-
partment. Interestingly, previous
genetic studies have indicated that
for patients undergoing stem cell
transplant, polymorphisms within
certain antioxidant genes are good
predictors of which patients will
develop mucositis (Hahn et al.,
2010). Hopefully, it won’t be long
before these patients, and count-
less others, can benefit from a
simple, molecular-based strategy
for this particularly vexing clinical
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